Pfizer's major customers
McKesson accounted for 25% of Pfizer's revenue in FY 2025, about the same as 23% a year earlier. 1 listed supplier reports Pfizer as a customer worth 10% or more of their revenue, led by Repligen at 10%.
Get an email when Pfizer's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Major customers of Pfizer
Customers that Pfizer named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| McKessonMCK | 25% | from 23% | 8 years | FY 2025 · filed 26 Feb 2026 |
| CencoraCOR | 16% | from 17% | 4 years | FY 2025 · filed 26 Feb 2026 |
| Cardinal HealthCAH | 13% | from 14% | 8 years | FY 2025 · filed 26 Feb 2026 |
Formerly disclosed
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Government And Government Sponsored | 23% | last FY 2022 | 2 years | FY 2022 · filed 23 Feb 2023 |
| Cencora Inc.Formerly Amerisource Bergen | 12% | last FY 2023 | 3 years | FY 2023 · filed 22 Feb 2024 |
| U.S. Government | 6% | last FY 2024 | 3 years | FY 2024 · filed 27 Feb 2025 |
| AmerisourceBergen | 5% | last FY 2022 | 5 years | FY 2022 · filed 23 Feb 2023 |
Suppliers that depend on Pfizer
Listed companies whose annual report names Pfizer as a customer worth 10% or more of their revenue. If Pfizer cuts orders or switches supplier, these are the companies that feel it.
| Supplier | Its revenue from this company | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| RepligenRGEN | 10% | from 11% | 2 years | FY 2021 · filed 22 Feb 2024 |
Formerly disclosed
| Supplier | Its revenue from this company | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| EyePointEYPT | 74% | last FY 2017 | 2 years | FY 2017 · filed 18 Sept 2018 |
| Maravai Lifesciences HoldingsMRVI | 26% | last FY 2022 | 3 years | FY 2022 · filed 18 Mar 2025 |
| PersonalisPSNL | 13% | last FY 2019 | 2 years | FY 2019 · filed 24 Feb 2022 |
| Nektar TherapeuticsNKTR | 12% | last FY 2024 | 4 years | FY 2024 · filed 13 Mar 2026 |
| Fuelcell EnergyFCEL | 2% | last FY 2022 | 6 years | FY 2022 · filed 20 Dec 2022 |
| Halozyme TherapeuticsHALO | 1% | last FY 2014 | 3 years | FY 2014 · filed 2 Mar 2015 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API